Mammalian Cell Fermentation Technology Market - By Type (Chinese Hamster Ovary (CHO), Human Embryonic Kidney (HEK)), Application (Monoclonal Antibodies, Recombinant Proteins), End-use (Biopharmaceutical Companies, CMOs & CDMOs) & Forecast, 2023-2032

Description

List of Tables

Mammalian cell fermentation technology industry size is expected to record 8.4% CAGR from 2023 to 2032 backed by the soaring demand for biopharmaceuticals, including vaccines, monoclonal antibodies, and therapeutic proteins. The need for efficient and scalable production processes, characterized by high yields and minimal contamination risks, has fueled the adoption of this technology.

Furthermore, there is growing focus on personalized medicine and regenerative therapies. For instance, in April 2023, Fujitsu and BSC announced a collaboration to improve their research on personalized medicine and quantum computing. This factor, along with the advancements in bioprocessing techniques, including single-use bioreactors and improved cell lines, for streamlining the manufacturing of biologics, will stimulate the market dynamics.

The mammalian cell fermentation technology market is classified based on type, application, end-use, and region.

The recombinant proteins segment will record 9.3% CAGR from 2023 to 2032 as they are widely employed in the biopharmaceutical industry for a myriad of therapeutic, diagnostic, and research purposes. Mammalian cell fermentation technology offers an ideal platform to produce high-quality recombinant proteins due to its ability to facilitate post-translational modifications, such as glycosylation, essential for the functionality of these proteins. The recombinant proteins application segment is poised to flourish as biopharmaceutical research continues to diversify and expand.

The biopharmaceutical companies segment is anticipated to observe 8% CAGR during 2023-2032. These companies are responsible for developing and manufacturing innovative biologics that cater to a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. The flexibility, scalability, and reliability of mammalian cell fermentation technology are highly valuable to biopharmaceutical firms seeking to optimize their production processes. The ability to produce biologics on a large scale, while ensuring product quality and consistency, positions the technology as a vital resource for these companies.

Asia Pacific mammalian cell fermentation technology industry size is predicted to witness 9.5% CAGR from 2023 to 2032 driven by a growing population, increasing healthcare expenditure, and a rising demand for advanced therapeutics. The region is home to numerous biopharmaceutical companies, research institutes, and contract manufacturing organizations that are keen to incorporate state-of-the-art technologies. As regulatory pathways become more streamlined and favorable, the APAC market is expected to experience substantial growth in the near future.

Product Code: 6524

Chapter 1 Methodology & Scope

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Global mammalian cell fermentation technology industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Type trends
- 2.1.4 Application trends
- 2.1.5 End-use trends

Chapter 3 Mammalian Cell Fermentation Technology Industry Insights

3.1 Industry landscape
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing demand for biologics
  - 3.2.1.2 Increasing investment in research and development of novel recombinant proteins
  - 3.2.1.3 Increasing focus on personalized medicine and precision medicine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost associated with the production of biologics using mammalian cell fermentation technology
  - 3.2.2.2 Regulatory challenges
3.3 Growth potential analysis
- 3.3.1 By type
- 3.3.2 By application
- 3.3.3 By end-use
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
- 3.5.1 U.S.
- 3.5.2 Europe
3.6 Technology landscape
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Company positioning matrix
4.5 Strategy dashboard, 2022

Chapter 5 Mammalian Cell Fermentation Technology Market, By Type, 2018 - 2032 (USD Million)

5.1 Key trends, by type
5.2 Chinese Hamster Ovary (CHO) cell fermentation
5.3 Human Embryonic Kidney (HEK) cell fermentation
5.4 Baby Hamster Kidney (BHK) cell fermentation
5.5 Murine myeloma cell fermentation
5.6 Other types

Chapter 6 Mammalian Cell Fermentation Technology Market, By Application, 2018 - 2032 (USD Million)

6.1 Key trends, by application
6.2 Monoclonal antibodies
6.3 Recombinant proteins
6.4 Vaccines
6.5 Hormones
6.6 Enzymes
6.7 Other applications

Chapter 7 Mammalian Cell Fermentation Technology Market, By End-use, 2018 - 2032 (USD Million)

7.1 Key trends, by end-use
7.2 Biopharmaceutical Companies
7.3 CMOs & CDMOs
7.4 Academic & Research Institutes

Chapter 8 Mammalian Cell Fermentation Technology Market, By Region, 2018 - 2032 (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 MEA
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 Rest of MEA

Chapter 9 Company Profiles

9.1 Thermo Fisher Scientific, Inc.
9.2 Merck KGaA
9.3 Danaher Corporation
9.4 Lonza Group Ltd
9.5 F. Hoffmann-La Roche Ltd
9.6 Sartorius AG
9.7 AstraZeneca PLC
9.8 Bristol-Myers Squibb Company
9.9 Amgen Inc.
9.10 Gilead Sciences, Inc.
9.11 Moderna, Inc.
9.12 Regeneron Pharmaceuticals, Inc.